Periodontal ligament (PDL) cells are comprised of heterogenous cell populations including mesenchymal stem cells and osteogenic progenitor cells. We previously reported that differentiation of human PDL cells into osteoblasts requires phosphoinositide 3-kinase (PI3K) activities. Here, we investigate osteoblast differentiation using TGF-1, BMP-2/BMP-7, and dexamethasone (Dex) in human PDL cells, focusing on the PI3K/Akt pathway. We found that in TGF-1-treated cells, Dex increased IGF-1 expression as well as phosphorylated Akt, which is a main target molecule of PI3K. Downregulation of IGF-1 expression and enhanced phosphorylation of Akt were observed in BMPs with Dex-treated cells, even though alkaline phosphatase expression and activities were enhanced. These results indicate that IGF-1 is a key regulator in TGF-1-induced osteogenesis, but it is not required in osteoblast differentiation initiated by BMPs. Because BMPs require PI3K activation for osteoblast differentiation, and because BMP treatment upregulates Akt phosphorylation, signaling molecules other than IGF-1 may support BMP-induced osteoblast differentiation.
Introduction
The periodontal ligament (PDL) is a connective tissue consisting of heterogeneous population which includes undifferentiated mesenchymal cells, osteoprogenitors, fibroblasts and cementoblasts. Cells in PDL exhibit the potential to differentiate into osteoblasts in vitro 1) . Some studies reported that human PDL contains stem cells and consequently PDL stem cells have the potential to generate cementum/PDL-like tissue 2, 3) . Therefore, PDL is featured as a useful source of regenerative therapy.
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the TGFfamily. They play a pivotal role in connective tissue regeneration and bone remodeling.
Previous reports demonstrated that BMP has significant effects in osteogenic differentiation and bone formation. In particular, BMP-2 and BMP-7 can strongly induce osteogenesis of bone marrow mesenchymal stem cells [4] [5] [6] . Furthermore, BMP-2/-7 heterodimers are usually the most potent osteogenic inducers 7) . Transforming growth factor (TGF) -1 is crucial for connective tissue regeneration and bone remodeling, as demonstrated by several in vivo and in vitro studies [8] [9] [10] [11] [12] . TGF-1 increases mRNA levels of osteoblast differentiation markers and alkaline phosphatase (ALP) activity in murine bone marrow stromal cells 11) . However, TGF-1 also blocks osteogenesis by various mechanisms depending on its concentration, the cell density, and differentiation stage of the cells 13) . Some studies reported that TGF-1 has biphasic and concentration-dependent effects on osteoblast differentiation [14] [15] [16] . We recently reported that repetitive TGF-1 administration negatively regulated osteoblast differentiation by down-regulation of Insulin-like growth factor-1 (IGF-1) production 17) . IGF-1 is one of the most abundant cytokines in bones and supposed to play an important role in osteogenesis.
Indeed, IGFs stimulate in vitro and in vivo osteoblast proliferation and differentiation through specific membrane receptors [18] [19] [20] [21] .
Although IGF-1 does not direct undifferentiated stromal cells to differentiate into cells of an osteoblast lineage, it enhances the function of mature osteoblasts 22) . Synthetic glucocorticoid dexamethasone (Dex) is generally a useful reagent for osteoblast differentiation 23) . However, it has both stimulatory and inhibitory effects on osteoblast differentiation depending upon the dose, has remained unclear although stem cells are attractive candidates for clinical application. And it is not clear that the combination of TGF-1 and Dex or BMP-2/-7 and Dex can stimulate osteoblast differentiation in PDL cells. In this study, we investigated that whether combination of TGF-1 and Dex or BMP-2/-7 and Dex associate with IGF-1 expression and stimulate osteoblast differentiation.
Materials and Methods

Cell culture and osteogenic differentiation
Human periodontal ligament (HPDL) cells were purchased from Lonza (Basel, Switzerland) and cultured in BulletKit ® Stromal cell growth medium (SCGM) (Lonza, Basel, Switzerland). HPDL cells of passages 5 to 8 were seeded at a density of 1 × 10 5 cells/cm 2 for each assay. Osteoblast differentiation was induced by replacing with the osteoblast differentiation medium (OBM), comprising -MEM (Invitrogen, Carlsbad, CA, USA) supplemented with 50 g/mL L-ascorbic acid (Wako Pure Chemical Industries Ltd., Osaka, Japan) and 10 mM -glycerophosphate (Wako,Tokyo,JAPAN), 1 ng/mL rhTGF-1 (Wako, Tokyo, Japan), 50 ng/mL BMP-2/-7 (R&D Systems, MN, USA), and 10 nM dexamethasone (Sigma-Aldrich, St. Louis, MO, USA), they were added on the following day. Under the single TGF-1 or BMP-2/ -7 administration condition, the medium was not changed until 72 hours, whereas under repeated TGF-1 administration condition, OBM containing fresh TGF-1 was changed after 12 hours. Control cells were treated identically except that they did not receive TGF-1, BMP-2/-7 and dexamethasone.
Alkaline phosphatase (ALP) staining
Seventy two hours after stimulation, cells were washed two times with phosphate-buffered saline (PBS), fixed with 4 % paraformaldehyde for 5 minutes at room temperature, and washed three times with distilled water. For staining, an ALP substrate solution (Roche Diagnostics, Basel, Switzerland) was added to the fixed cells for 60 minutes at room temperature. After staining, cells were washed three times with distilled water and images were scored.
Quantitative real time-PCR
Real time-PCR was used to examine the expression of osteoblast differentiation markers. After incubating for 72 hours in the differentiation medium, total RNA was extracted from cultured cells by using QIAzol reagent (Qiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. cDNA was synthesized using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA). Real time-PCR analysis was performed using the Premix Ex Taq TM reagent (Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions. Target genes included alkaline phosphatase (ALP), insulin-like growth factor 1 (IGF-1) and Pregnancy-associated plasma protein-A (PAPP-A).
18S rRNA was used as an internal control. All primers and probes are presented in Table. 1 was designed using Probefinder v2.45 (http://qpcr.probefinder.com/roche3.html).
Protein extraction and immunoblotting
Cells were lysed with lysis buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, complete protease inhibitor mixture, 1 mM sodium orthovanadate, and 1 % NP-40), and the protein content was measured using a DC Protein Assay Kit (Bio-Rad, Marnes-la-Coquette, France). Equivalent protein concentrations were resolved by electrophoresis on NuPAGE 4%-12% Bis-Tris gels (Invitrogen) and transferred to a PVDF membrane. The membrane was probed with anti-phosphorylated Akt (1:2000; Cell Signaling Technology Inc., Danvers, MA, USA) and anti-IGF-1 (1:2500; Abcam, Cambridge, UK) antibodies, followed by HRP-conjugated goat anti-rabbit IgG. Bound antibodies were visualized using a chemiluminescent substrate (ECL plus; GE Healthcare UK Ltd., Buckinghamshire) and ImageQuant LAS 4000 mini (GE healthcare).
Statistical analysis
All data are expressed as mean ± S.D. When ANOVA indicated differences among the groups, multiple comparisons between each experimental group were performed using the Bonferroni test. Statistical significance was defined as p < 0.05, p < 0.001. 
Results
mRNA expression of ALP and ALP activity staining
As shown in Fig. 1A , single treatment with TGF-1 was more induced ALP expression, an early mineralization marker indicating commitment to osteoblast differentiation, compared to BMP-2/-7 treatment. Repeated treatment with TGF-1 markedly suppressed ALP expression. Addition of Dex to TGF-1 or BMP-2/-7 more upregulated ALP mRNA expression than TGF-1 or BMP-2/-7 alone (Fig. 1B) .
mRNA expression of IGF-1 and PAPP-A
In TGF-1 treated cells, IGF-1 mRNA expression was more induced by Dex addition ( Fig. 2A) . However, IGF-1 mRNA expression was significantly suppressed by Dex addition in BMP-2/-7 treated cells ( Fig. 2A) . Similarly, PAPP-A mRNA expression was decreased in BMP-2/-7 treatment cells by Dex addition (Fig.  2B) .
Expression of IGF-1 and p-Akt protein
As shown in Fig. 3 , IGF-1 protein level in TGF-1 treatment cells was higher than BMP-2/-7 treatment. Repeated TGF-1 administration significantly decreased IGF-1 protein level. Dex addition increased IGF-1 protein level in TGF-1 treated cells.
However, in cells treated with BMP-2/-7, Dex inhibited the IGF-1 protein level as shown in repeated TGF-1 administration group.
Similarly, the protein level of p-Akt, a downstream effector of PI3K, in TGF-1-treated cells was higher than in cells treated with BMP-2/-7. Akt phosphorylation was dramatically reduced after repeated TGF-1 treatment. Dex addition significantly augmented the p-Akt protein level in both TGF-1-treated and BMP-2/-7-treated cells.
Discussion
In this article, we describe that Dex combined with BMP-2/-7-induced osteoblast differentiation of HPDL cells independently of IGF-1 expression, although Dex combined with TGF-1induced osteoblast differentiation associated with IGF-1 expression.
IGF-1 is expressed by osteoblasts and has modest effects on the proliferation of cells of the osteoblast lineage. IGF-1 enhances the function of the mature osteoblasts, although IGF-1 does not direct the differentiation of undifferentiated stromal cells toward cells of the osteoblast lineage. The IGF-1 gene knockout mice revealed that the fetal mice demonstrated short-limb dwarfism delays in mineralization and increased chondrocyte apoptosis 25) .
The combined delivery of BMP-7 and IGF-1 genes synergistically enhanced the differentiation of HPDL cells while suppressing their proliferation 21) . We previously reported that a single low dose of TGF-1 treatment promoted osteoblast differentiation whereas treatment with repetitive low doses, or a single high dose, of TGF-1 had much weaker effects in osteoblast differentiation. Moreover, we found that this osteogenesis by TGF-1 is caused by IGF-1 production. Inhibition of IGF-1 signaling using small interfering RNA (siRNA) against insulin receptor substrate-1 (IRS-1) suppressed mRNA expression of RUNX2, ALP, BSP, and IGF-1 even with single TGF-1 administration. Exogenous and overexpressed IGF-1 recovered ALP activity and mRNA expression of osteoblast differentiation marker genes even with repeated TGF-1 administration. Thus, IGF-1 plays a central role of osteoblast differentiation 13) .
BMP-2, an agent that enhances osteoblast differentiation and function, increases IGF-1 synthesis in osteoblasts 26) . The synthetic glucocorticoid Dex is generally a useful reagent for osteoblast differentiation 23) . However, it has both stimulatory and inhibitory effects on osteoblast differentiation depending upon the dose, duration, stage of cell differentiation and species of responding cell 24, 27) . At the same time, it is catabolic factor inducing bone loss or osteoporosis with prolonged administration in human system 28) .
Sun et al. reported that Dex decreased mRNA expression of ALP and 2 (I) collagen in mouse dental papillae cell line MDPC-23 29) . We therefore investigated the effect of Dex on osteoblast differentiation induced by TGF-1 or BMP-2/-7 in HPDL cells since Dex has biphasic effects on osteoblast differentiation by various conditions such as Dex concentration and cell types.
Both TGF-1 and BMP-2/-7 were capable of inducing osteoblast differentiation of HPDL cells, and TGF-1 was higher in its potency than BMP-2/-7 ( Fig. 1 ). Dex combined with TGF-1 and BMP-2/-7 increased ALP mRNA expression. IGF-1 production play a central role in TGF-1 -induced osteoblast differentiation. Dex combined with TGF-1 increased IGF-1 expression compared to TGF-1 alone. However, BMP-2/-7 with Dex treatment suppressed IGF-1 mRNA expression and protein production and PAPP-A mRNA expression compared to BMP-2/ -7 alone (Figs. 2 and 3 ). PAPP-A is a matrix metalloprotease which specifically cleaves IGF binding protein (IGFBP)-2, -4, -5 and increases IGF-1 bioavailability 30) . These results suggest that the mechanism of BMP-2/-7-induced osteoblast differentiation of HPDL cells may differs from that of TGF-1. Therefore, TGF-1 regulates osteoblast differentiation via IGF-1 production, BMP-2/-7 may regulate through IGF-1 along with alternative mechanisms.
PI3K/Akt pathway is known that IGF-1 activates this pathway and play an important role in cellular growth, differentiation and metabolism. Repeated TGF-1 treatment markedly inhibited IGF-1 expression and subsequently Akt phosphorylation (Fig. 3) . These results suggest that the inhibition of osteoblast differentiation caused by repeated TGF-1 treatment is associated with the downregulation of IGF-1 expression and Akt inactivation. As shown in Fig. 3 , p-Akt was markedly increased by Dex addition in TGF-1 and BMP-2/-7 treated cells. It is thought that Dex could pass a cell membrane easily and then arrive at the nucleus, and finally transmit every signal because it is a steroidal hormone. Therefore, in BMP-2/-7 treatment cells Dex addition could induce osteoblast differentiation such as up-regulation of ALP mRNA expression independently of IGF-1 production.
In conclusion, Dex combined with TGF-1 promotes osteoblast differentiation via IGF-1 expression. However, unlike TGF-1, Dex combined with BMP-2/-7 promotes osteoblast differentiation independently of IGF-1 expression. We suggest that although TGF-1 and BMP-2/-7 belong to the same TGF-family and have an ability to induce the osteoblast differentiation, the mechanism of osteoblast differentiation is different. Further studies of Dex combined with these cytokine will help to clarify the osteoblast differentiation of HPDL cells and possibly lead to the development of novel bone-forming drug.
